



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

2nd July, 2013

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001.

The Manager – Listing
National Stock Exchange of India Ltd
"Exchange Plaza",
Bandra – Kurla Complex,
Bandra (E),
Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclosed a press note issued by our Company for your information and records.

Thanking you,

Yours faithfully,
For Natco Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)

Encl: a.a.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

July 2, 2013

NATCO announces marketing approval
for Rizatriptan (ODT), commences shipments

NATCO Pharma Limited is pleased to announce the receipt of marketing approval for its Rizatriptan Benzoate (Maxalt-MLD) – orally disintegrating tablets, 5 mg and 10 mg (base). The Company has already commenced shipments of the product, which is being launched by its marketing partner – Breckenridge Pharmaceuticals. Rizatriptan is used to treat **migraine headaches with or without aura** (warning signs that occur prior to the onset of a migraine headache).

NATCO estimates the market to be around US \$ 250 Million (before generic launch – as of December, 2012).

Forwarded for favor of publication

For NATCO Pharma Limited

Dr. Bhaskara Narayana. P.
Director & Chief Financial Officer